POZEN (POZN $3.80 +0.18) announced that it has sold most of the future royalty and milestone payments of Treximet, and will record the $75 million purchase price, less transaction costs, as revenue in the fourth quarter of 2011.
Therefore, the company is revising earlier estimated full year 2011 revenue to be in the range of $86-$87 million. Consensus had called for $17.37 million in revenues, with prior guidance for $18-19 million.






